Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Embody vs LVNG RX

Embody
Graded #52

Higher grade

vs+14
LVNG RX
Graded #268

Lower grade

The verdict

Embody takes it — 76.5/100 to 62.5/100.

Embody grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Embody offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEmbody +24
88
64
Dose & formulationEmbody +19
83
64
Clinical oversightEmbody +27
83
56
Labs & monitoringLVNG RX +8
54
62
FulfillmentEmbody +24
93
69
Contract termsLVNG RX +36
25
61
Embody · left barLVNG RX · right bar

The numbers

MetricEmbodyLVNG RX
WeighScore76.5/10062.5/100
GradeCC
Scorecard rank#52#268
Semaglutide$79/mo (all doses, promotional rate, compounded)$149/mo (starting dose, compounded)
Tirzepatide$129/mo (all doses, promotional rate, compounded)$249/mo (microdose tier, starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Embody

Graded #52 · C

Strengths

  • Among the lowest flat rates in the compounded segment — $79/mo semaglutide and $129/mo tirzepatide injection at every dose
  • Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
  • Available in all 50 states with no insurance friction
  • 24/7 unlimited clinician messaging and dose-adjustment support included
  • Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine

Where it loses points

  • The $79 flat rate relies on an auto-applied promo 'locked forever' — list price in the terms is $199/mo and reviewers allege the lock isn't honored
  • Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
  • Pharmacy partners not publicly named — compounding source transparency is limited
  • Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
LVNG RX

Graded #268 · C

Strengths

  • One bundled price covers the provider visit, prescription, shipping and ongoing check-ins, with zero consultation charges
  • States you are charged nothing if a provider does not approve you for treatment
  • Promises no dose-change surcharges — 'the price we quote is the price you pay, period'
  • Semaglutide from $149/mo is competitive against the wider compounded market
  • Offers a lower-dose GLP-1 microdose program alongside standard semaglutide and tirzepatide

Where it loses points

  • Displays a Trustpilot 'Rated Excellent 4.8 / 5' badge, but no Trustpilot profile exists for the domain or the brand
  • Also claims '4.9 based on 300+ Google reviews'; no Google listing for the business could be located
  • Its own homepage figures conflict — '10k+' members in the hero versus '1,743+ patients supported' in the counters below
  • The actual plan price is confirmed only after provider review, and the three treatment pages publish no prices at all
  • No compounding pharmacy, medical group or individual clinician is named anywhere on the site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard